5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
2
0
0
Last 30D
0
0
1
0
0
1M Ago
2
1
1
0
0
2M Ago
0
0
0
0
0
3M Ago
0
0
0
0
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 65.0% from the previous average price target of $4.00.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Mersana Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Brian Cheng
JP Morgan
Announces
Neutral
$5.00
-
David Nierengarten
Wedbush
Raises
Outperform
$7.00
$2.00
Asthika Goonewardene
Truist Securities
Maintains
Buy
$9.00
$9.00
Colleen Kusy
Baird
Raises
Neutral
$5.00
$1.00
Michael Schmidt
Guggenheim
Announces
Buy
$7.00
-
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Mersana Therapeutics. ...Full story available on Benzinga.com
Benzinga
